Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight

The Interleukin-13 inhibitors market is witnessing robust growth, driven by the rising prevalence of atopic dermatitis, asthma, and other type 2 inflammatory diseases. Additionally, the expected launch of therapies such as ASLAN Pharmaceuticals' Eblasakimab, UCB Pharma's Galvokimig, and...